4 completed, 3 active not recruiting, 1 not yet recruiting. 8 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Active not recruiting 3, Not yet recruiting 1 |
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
Follow IBI362: new trials by email Literature Review of IBI362 trials Research Report on IBI362
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer Mazdutide(Dual GLP-1R/GCGR Agonist), Placebo, Levonorgestrel-releasing intrauterine system - Obesity, Overweight | Phase 2 | Not yet recruiting | Tongji Hospital | 128 | 2026-11-01 | 2026-08-24 |
| A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) Placebo, IBI362 - Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 181 | 2025-06-20 | 2026-10-20 |
| Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity Tirzepatide, Placebo, IBI362 - Obesity | Phase 1 / Phase 2 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 98 | 2025-06-17 | 2025-12-15 |
| A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity placebo, IBI362 - Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF) | Phase 2 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 141 | 2025-03-26 | 2026-09-22 |
| A Study of IBI362 in Chinese Patients With Type 2 Diabetes IBI362, placebo, Dulaglutide - Type 2 Diabetes | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 252 | 2021-09-06 | 2023-12-27 |
| A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects IBI362, placebo - Overweight/ Obesity | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 328 | 2021-06-08 | 2025-11-17 |
| Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM IBI362, Placebo, Dulaglutide - Type 2 Diabetes | Phase 1 / Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 42 | 2020-09-12 | 2021-07-23 |
| Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects IBI362, Placebo - Overweight or Obesity | Phase 1 / Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 60 | 2020-06-16 | 2023-11-28 |
Obesity (4) · Diabetes Mellitus, Type 2 (2) · Overweight (2) · Endometrial Hyperplasia (1) · Endometrial Neoplasms (1)
Innovent Biologics (Suzhou) Co. Ltd. (7) · Tongji Hospital (1)
China (8)
Gang Chen, Principal Investigator (1)
PMID 34430840, PMID 35750681, PMID 36247927, PMID 37943529, PMID 38092790, PMID 41875890